3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Phase 4
1
Phase 1/2
1
Status
Terminated
2
Completed
2
Unknown
1
Recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Non-Small-Cell Lung
155
Neoplasms
115
Colorectal Neoplasms
97
Breast Neoplasms
92
Pancreatic Neoplasms
80
Neoplasm Metastasis
80
Leukemia, Myeloid, Acute
79
Recurrence
76
Melanoma
74
Prostatic Neoplasms
73
Ovarian Neoplasms
73
Multiple Myeloma
66
Stomach Neoplasms
59
Squamous Cell Carcinoma of Head and Neck
55
Lung Neoplasms
55
Triple Negative Breast Neoplasms
50
Glioblastoma
48
Lymphoma
47
Endometrial Neoplasms
43
Carcinoma, Hepatocellular
42
Advanced Solid Tumor
42
Lymphoma, Non-Hodgkin
41
Precursor Cell Lymphoblastic Leukemia-Lymphoma
40
Advanced Solid Tumors
37
Small Cell Lung Carcinoma
35
Uterine Cervical Neoplasms
34
Carcinoma, Renal Cell
34
Lymphoma, Large B-Cell, Diffuse
32
Lymphoma, B-Cell
32
Sarcoma
29
Interventions
olaparib
1
Pluvicto
1
Abiraterone Acetate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Recruiting
×
Genital Neoplasms, Male
×
Clear all
NCT06785636
2026-04-24
P300
Pathos AI, Inc.
Phase 1/2
Recruiting
252 enrolled